Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Ocrelizumab is a B cell-depleting drug widely used in relapsing–remitting multiple sclerosis (RRMS) and primary-progressive MS. In RRMS, it is becoming increasingly apparent that accumulation of disability not only manifests as relapse-associated worsening (RAW) but also as progression independent o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingwersen, J., Masanneck, L., Pawlitzki, M., Samadzadeh, S., Weise, M., Aktas, O., Meuth, S. G., Albrecht, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495413/
https://www.ncbi.nlm.nih.gov/pubmed/37696848
http://dx.doi.org/10.1038/s41598-023-40940-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495413/
https://www.ncbi.nlm.nih.gov/pubmed/37696848
http://dx.doi.org/10.1038/s41598-023-40940-w

Ejemplares similares